Whittier Trust Co. of Nevada Inc. Has $1.13 Million Stake in IQVIA Holdings Inc. $IQV

Whittier Trust Co. of Nevada Inc. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 90.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,484 shares of the medical research company’s stock after selling 49,196 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in IQVIA were worth $1,133,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Asset Dedication LLC lifted its holdings in IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares during the last quarter. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA during the 2nd quarter valued at approximately $39,000. J.Safra Asset Management Corp grew its holdings in shares of IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the last quarter. Rothschild Investment LLC increased its position in IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares during the period. Finally, Root Financial Partners LLC acquired a new position in shares of IQVIA during the third quarter worth $43,000. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on IQV shares. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Sunday. Mizuho set a $266.00 price objective on IQVIA in a research note on Friday, January 9th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Thursday. UBS Group boosted their price target on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Stifel Nicolaus boosted their target price on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $251.06.

IQVIA Price Performance

IQV stock opened at $238.15 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The business has a 50-day simple moving average of $229.57 and a two-hundred day simple moving average of $206.73. The company has a market capitalization of $40.56 billion, a P/E ratio of 32.58, a price-to-earnings-growth ratio of 2.39 and a beta of 1.36. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $2.84 earnings per share. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.